Preliminary studies of 6 beta-hydroxydexamethasone and its importance in the DST.

Published

Journal Article

The role of the metabolites of dexamethasone (DEX) in the dexamethasone suppression test (DST) has never been fully elucidated. We report here our preliminary studies of 6 beta-hydroxydexamethasone (6 OH-Dex), a known metabolite of DEX, on the hypothalamic-pituitary-adrenal (HPA) axis of the rat; its activity in the most commonly used radioimmunoassay for plasma DEX; and its plasma concentrations in a normal human subject during the standard 1.0 mg DST. Six OH-Dex administered subcutaneously to rats at a dose of 1 mg/kg was able to completely suppress corticosterone production for at least 3 hr. In the IgG Corp. radioimmunoassay for plasma DEX, 6 OH-Dex was moderately cross-reactive yielding a 50% cross-reactivity of 10%. Gas chromatographic coupled mass spectroscopic analysis of human plasma samples, obtained 12 to 20 hr after the oral ingestion of 1.0 mg DEX, demonstrated similar plasma concentrations for both the parent compound and the 6-hydroxyl metabolite. The relevance of these findings, particularly to pharmacokinetic studies of the DST, is discussed.

Full Text

Cited Authors

  • Ritchie, JC; Owens, MJ; Mayer, H; Watson, JT; Kilts, C; Carroll, BJ

Published Date

  • November 1, 1992

Published In

Volume / Issue

  • 32 / 9

Start / End Page

  • 825 - 833

PubMed ID

  • 1450296

Pubmed Central ID

  • 1450296

International Standard Serial Number (ISSN)

  • 0006-3223

Digital Object Identifier (DOI)

  • 10.1016/0006-3223(92)90086-f

Language

  • eng

Conference Location

  • United States